San Diego-based mostly Viking Therapeutics marked itself as a serious competitor from the weight loss drug market in February immediately after revealing promising data from a mid-phase trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when supplied like a weekly injection As well as in March t